ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Roma, Lazio

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Endometrial Cancer
Carcinoma
Breast Cancer
Fallopian Tube Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near Roma, Lazio, ITA:

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...

Active, not recruiting
Relapsed Ovarian Cancer
Following Complete or Partial Response to Platinum Based Chemotherapy
Drug: Placebo to match olaparib 300mg
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Roma, Italy and 125 other locations

followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...

Active, not recruiting
Advanced Ovarian Cancer
Drug: Bevacizumab
Drug: Durvalumab placebo

Phase 3

AstraZeneca
AstraZeneca

Roma, Italy and 213 other locations

of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...

Active, not recruiting
Ovarian Cancer
Drug: Alpelisib
Drug: Pegylated liposomal doxorubicin (PLD)

Phase 3

Novartis
Novartis

Roma, RM, Italy and 92 other locations

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....

Active, not recruiting
Advanced Ovarian Cancer
FIGO Stage III-IV
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Roma, Italy and 176 other locations

therapy for the treatment of participants with advanced/recurrent ovarian cancer.Substudy 1 will investigate the safety, tolerabili...

Not yet enrolling
Advanced/Recurrent Ovarian Cancer
Drug: Saruparib

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Rome, Italy and 22 other locations

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (I...

Enrolling
Low Grade Serous Ovarian Cancer
Drug: Defactinib
Drug: Letrozole

Phase 3

Verastem

Roma, Italy and 102 other locations

to evaluate efficacy and safety of intermittent dosing of relacorilant in combination with nab-paclitaxel and bevacizumab in patients with ovarian...

Enrolling
Peritoneal Neoplasms
Fallopian Tube Cancer
Drug: Nab-paclitaxel 80 mg/m^2
Drug: Relacorilant 150 mg once daily (QD)

Phase 2

Corcept Therapeutics
Corcept Therapeutics

Rome, Italy and 38 other locations

Status recently updated

with either niraparib or lartesertib in participants with epithelial ovarian cancer and to assess any differences between tuvuserti...

Enrolling
Active, not recruiting
Ovarian Cancer
Drug: Niraparib
Drug: Tuvusertib (M1774)

Phase 2

Merck KGaA (EMD Serono)
Merck KGaA (EMD Serono)

Rome, Italy and 83 other locations

of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus* The study wil...

Enrolling
Endometrial Cancer
Recurrent Primary Peritoneal Cancer
Drug: Sarilumab
Drug: Ubamatamab

Phase 1, Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Roma, Lazio, Italy and 53 other locations

Locations recently updated

(ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the...

Enrolling
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Drug: azenosertib

Phase 2

K-Group Beta

Rome, Lazio, Italy and 69 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems